Post-endoscopy upper gastrointestinal cancer in a United States multicenter cohort: site- and risk-stratified trends and survival
Endoscopy · 13.10.2026
DOI: 10.1055/a-2948-3126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 13.10.2026. Verfasst von Butros Fakhoury und 11 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University, Department of Internal Medicine, Virginia, United States, Richmond. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Post-endoscopy upper gastrointestinal cancer (PEUGIC) is an emerging quality metric, but varying definitions complicate benchmarking. We characterized PEUGIC rates and outcomes by anatomic site and coded high-risk condition (HRC) status in a large US cohort. This was a retrospective cancer-first cohort study of 14 814 patients with upper gastrointestinal cancer (UGIC) from a multicenter database (2016–2024). Index endoscopy-detected UGIC was diagnosed within 6 months of esophagogastroduodenoscopy. PEUGIC was defined as UGIC diagnosed 6–36 months after a nondiagnostic esophagogastroduodenoscopy. The primary outcome was PEUGIC rate by cancer type and HRC status. Secondary outcomes included 3-year overall survival. The overall PEUGIC rate was 9.4% (esophageal cancer 9.6%, gastric cancer 8.6%, duodenal cancer 10.7%). Rates were higher with HRC (18.2%) than without HRC (5.0%; P < 0.001). PEUGIC rate without HRC plateaued (4.0%–5.1% in 2022–2024), while PEUGIC rate with HRC for esophageal cancer (16.8%) and gastric cancer (14.4%) decreased over time. In exploratory analysis, PEUGIC was associated with better survival vs. index endoscopy-detected UGIC for esophageal cancer (adjusted hazard ratio [aHR] 0.82, 95%CI 0.67–0.99) and gastric cancer (aHR 0.77, 0.62–0.96), and PEUGIC with HRC was associated with lower mortality vs. PEUGIC without HRC for esophageal cancer (aHR 0.51, 0.36–0.74) and gastric cancer (aHR 0.50, 0.34–0.73). 1 in 10 UGIC patients had a prior nondiagnostic endoscopy within 3 years. PEUGIC rates varied by anatomic site and HRC status, suggesting site- and HRC-stratified benchmarks may better capture endoscopic performance than aggregate metrics.
Autor:innen und Institutionen
- Virginia Commonwealth University, Department of Internal Medicine, Virginia, United States, Richmond.
- Virginia Commonwealth University, Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia, United States, Richmond.
- University of Kansas Medical Center, Division of Gastroenterology, Hepatology and Motility, Kansas, United States, Kansas City.
- Cleveland Clinic Foundation, Department of Internal Medicine, Ohio, United States, Cleveland.
- Texas Tech University Health Sciences Center, Department of Internal Medicine, Texas, United States, Lubbock.
- Humanitas University, Department of Biomedical Sciences, Italy, Milan.
ORCID-Profile: Butros Fakhoury, Sachin Srinivasan, Cesare Hassan
Zitieren
APA
Fakhoury, B., Jahagirdar, V., Srinivasan, S., Sierra, L., Danpanichkul, P., Patel, K. S., Hassan, C., Alexandre, L., Thosani, N., Trudgill, N., Sharma, P., & Desai, M. (2026). Post-endoscopy upper gastrointestinal cancer in a United States multicenter cohort: site- and risk-stratified trends and survival. Endoscopy. https://doi.org/10.1055/a-2948-3126
Vancouver
Fakhoury B, Jahagirdar V, Srinivasan S, Sierra L, Danpanichkul P, Patel KS, et al. Post-endoscopy upper gastrointestinal cancer in a United States multicenter cohort: site- and risk-stratified trends and survival. Endoscopy. 2026. doi:10.1055/a-2948-3126
BibTeX
@article{Fakhoury2026,
author = {Fakhoury, Butros and Jahagirdar, Vinay and Srinivasan, Sachin and Sierra, Leandro and Danpanichkul, Pojsakorn and Patel, Krishan S and Hassan, Cesare and Alexandre, Leo and Thosani, Nirav and Trudgill, Nigel and Sharma, Prateek and Desai, Madhav},
title = {Post-endoscopy upper gastrointestinal cancer in a United States multicenter cohort: site- and risk-stratified trends and survival},
journal = {Endoscopy},
year = {2026},
doi = {10.1055/a-2948-3126}
}
EUVIMED